Biocure Technology, Inc. engages in the development and commercialization of biosimilar products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2008-03-27. The firm specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.
Biocure Technology Inc en büyük gelir kaynağı Tai Er olup, en son kar bildiriminde geliri 4,946,972,057 dir. Coğrafi olarak, China , Biocure Technology Inc için ana pazar olup, geliri 6,614,352,119 dir.